Skip to main content
Top
Published in: Diabetologia 9/2013

Open Access 01-09-2013 | Short Communication

Improved genetic testing for monogenic diabetes using targeted next-generation sequencing

Authors: S. Ellard, H. Lango Allen, E. De Franco, S. E. Flanagan, G. Hysenaj, K. Colclough, J. A. L. Houghton, M. Shepherd, A. T. Hattersley, M. N. Weedon, R. Caswell

Published in: Diabetologia | Issue 9/2013

Login to get access

Abstract

Aims/hypothesis

Current genetic tests for diagnosing monogenic diabetes rely on selection of the appropriate gene for analysis according to the patient’s phenotype. Next-generation sequencing enables the simultaneous analysis of multiple genes in a single test. Our aim was to develop a targeted next-generation sequencing assay to detect mutations in all known MODY and neonatal diabetes genes.

Methods

We selected 29 genes in which mutations have been reported to cause neonatal diabetes, MODY, maternally inherited diabetes and deafness (MIDD) or familial partial lipodystrophy (FPLD). An exon-capture assay was designed to include coding regions and splice sites. A total of 114 patient samples were tested—32 with known mutations and 82 previously tested for MODY (n = 33) or neonatal diabetes (n = 49) but in whom a mutation had not been found. Sequence data were analysed for the presence of base substitutions, small insertions or deletions (indels) and exonic deletions or duplications.

Results

In the 32 positive controls we detected all previously identified variants (34 mutations and 36 polymorphisms), including 55 base substitutions, ten small insertions or deletions and five partial/whole gene deletions/duplications. Previously unidentified mutations were found in five patients with MODY (15%) and nine with neonatal diabetes (18%). Most of these patients (12/14) had mutations in genes that had not previously been tested.

Conclusions/interpretation

Our novel targeted next-generation sequencing assay provides a highly sensitive method for simultaneous analysis of all monogenic diabetes genes. This single test can detect mutations previously identified by Sanger sequencing or multiplex ligation-dependent probe amplification dosage analysis. The increased number of genes tested led to a higher mutation detection rate.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281PubMedCrossRef Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281PubMedCrossRef
2.
go back to reference Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477PubMedCrossRef Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477PubMedCrossRef
3.
go back to reference Ellard S, Thomas K, Edghill EL et al (2007) Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 50:2313–2317PubMedCrossRef Ellard S, Thomas K, Edghill EL et al (2007) Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 50:2313–2317PubMedCrossRef
4.
go back to reference Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553PubMedCrossRef Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553PubMedCrossRef
5.
go back to reference Rossetti S, Hopp K, Sikkink RA et al (2012) Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23:915–933PubMedCrossRef Rossetti S, Hopp K, Sikkink RA et al (2012) Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23:915–933PubMedCrossRef
6.
go back to reference Redin C, Le Gras S, Mhamdi O et al (2012) Targeted high-throughput sequencing for diagnosis of genetically heterogeneous diseases: efficient mutation detection in Bardet–Biedl and Alström syndromes. J Med Genet 49:502–512PubMedCrossRef Redin C, Le Gras S, Mhamdi O et al (2012) Targeted high-throughput sequencing for diagnosis of genetically heterogeneous diseases: efficient mutation detection in Bardet–Biedl and Alström syndromes. J Med Genet 49:502–512PubMedCrossRef
7.
go back to reference O’Sullivan J, Mullaney BG, Bhaskar SS et al (2012) A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet 49:322–326PubMedCrossRef O’Sullivan J, Mullaney BG, Bhaskar SS et al (2012) A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet 49:322–326PubMedCrossRef
8.
go back to reference Lango Allen H, Flanagan SE, Shaw-Smith C et al (2011) GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nature Genetics 1:20–22CrossRef Lango Allen H, Flanagan SE, Shaw-Smith C et al (2011) GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nature Genetics 1:20–22CrossRef
9.
go back to reference Edghill EL, Stals K, Oram RA, Shepherd MH, Hattersley AT, Ellard S (2013) HNF1B deletions in patients with young-onset diabetes but no known renal disease. Diabet Med 30:114–117PubMedCrossRef Edghill EL, Stals K, Oram RA, Shepherd MH, Hattersley AT, Ellard S (2013) HNF1B deletions in patients with young-onset diabetes but no known renal disease. Diabet Med 30:114–117PubMedCrossRef
Metadata
Title
Improved genetic testing for monogenic diabetes using targeted next-generation sequencing
Authors
S. Ellard
H. Lango Allen
E. De Franco
S. E. Flanagan
G. Hysenaj
K. Colclough
J. A. L. Houghton
M. Shepherd
A. T. Hattersley
M. N. Weedon
R. Caswell
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2962-5

Other articles of this Issue 9/2013

Diabetologia 9/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.